Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)
What is the purpose of this trial?
To evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD.
- Ages50 - 80 years
- Trial withBiogen MA, Inc.
- Start Date10/24/2018
- End Date07/20/2021
- Last Updated04/23/2019
- Study HIC#2000023510